Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107). Background: Historically, recurrent glioblastoma (GBM) has a median ...
NEO100-01, an intranasal perillyl alcohol therapy, targets IDH1-mutant astrocytomas, aiming to bypass the blood-brain barrier. The phase 2a trial is nearing full enrollment, conducted at seven U.S.
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results